You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Prototype Development for 8,000 Samples per Second 3D SADAR and Rapidly Deployable Sensor Hardware
SBC: QUANTUM TECHNOLOGY SCIENCES, INC. Topic: A09099Quantum has two technical objectives for Phase II. The first is to develop, test, demonstrate, and deliver prototype three-dimensional (3D) array, Seismic Acoustic Detection and Ranging (SADAR) systems with a data sampling rate of 8,000 (8K) per second to automatically detect, classify, report, and localize underground sources for specific seismic-acoustic signals of interest in near real-time. Th ...
SBIR Phase II 2016 Department of DefenseAir Force -
A Novel Coverglass System with Enhanced Radiation Resistance
SBC: Infoscitex Corporation Topic: AF04029The Foster-Miller team is developing a novel coverglass system that protects photovoltaic cells on space power systems that are exposed to high doses of ionizing radiation. The spectrum of radiation a solar cell is exposed to not only provides usable energy, over time it also reduces the efficiency of the cell by darkening the barrier coverglass, escalates the operating temperature, and deteriora ...
SBIR Phase II 2005 Department of DefenseAir Force -
Prophylactic Anthrax Toxin Vaccine
SBC: VICAL, INC. Topic: N/ADESCRIPTION (provided by applicant): Vical Inc. seeks SBIR Phase II funding to develop and produce a licensable prophylactic anthrax vaccine. This project will move on an accelerated but realistic timeline with plans for human clinical trials to begin in September 2003. Although many candidate vaccines are being studied for anthrax prevention or post-exposure prophylaxis, the Vical approach has ...
STTR Phase II 2003 Department of Health and Human ServicesNational Institutes of Health -
Side Channel Attack Testbench Emulator (SCATE)
SBC: Intrinsix Corp. Topic: HR001119S003505Side channel analysis (SCA) and fault injection (FI) are a solid part of the relevant attack space for any chip that can be physically reached by an attacker. These hardware attacks allow key extraction from cryptographic implementations, and fault injection specifically allows complete takeover of devices. Current commercial chip design tools do not offer integrated analysis to verify resistance ...
SBIR Phase II 2021 Department of DefenseDefense Advanced Research Projects Agency -
Integrated, self-actuated, blood collection and biomarker purification device
SBC: Tasso, Inc Topic: SB122003Blood-based point-of-care (POC) diagnostics or remote diagnostics that require specialized equipment only available in centralized, commercial laboratories are currently limited by major logistical and technical barriers. Blood collection can be a traumatic, inconvenient, and inconsistent process that is based on decades-old technologies, such as the lancet-puncture, that are not amenable to new P ...
SBIR Phase II 2014 Department of DefenseDefense Advanced Research Projects Agency -
Development and validation of therapy for mucopolysaccharidosis III
SBC: Phoenix Nest Inc. Topic: 103Project Summary Sanfilippo disease (mucopolysaccharidosis type III; MPS III) is a devastating neurodegenerative lysosomal storage disorder of childhood whose pathologic features are neurologic: slowing of development, severe behavioral problems, progressive cognitive decline, dementia, and decline in motor skills leading to immobility, unresponsiveness, and death. We have focused on MPS IIID cause ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Development and Optimization of MNK Inhibitors for the Treatment of Neuropathic Pain
SBC: 4E THERAPEUTICS, INC. Topic: 104Abstract The goal of this project is to develop an optimized MNK inhibitor for neuropathic pain treatment. MNK is a kinase that phosphorylates eIF4E to control the translation of a distinct subset of mRNAs. Our focus on this target for neuropathic pain is grounded in evidence that MNK-eIF4E signaling is activated in nociceptors upon exposure to pain promoting cytokines and growth factors as well a ...
SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health -
Motion-robust brain MRI for infants
SBC: TURING MEDICAL TECHNOLOGIES INC Topic: 101Project Abstract/Summary The objective of this SBIR/STTR Fast Track submission is to provide a software solution to reduce the effects of head motion during brain MRIs of infants. Because structural MRI scanning produces high-resolution images and does not expose patients to radiation, it has become an immensely valuable diagnostic tool, particularly for imaging the brain in infant samples. Approx ...
SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health -
Engineering Sensors for Towed Array Reliability
SBC: 3 Phoenix, Inc. Topic: N111075The operational need for this improved towed array technology insertion initiative stems from the necessity to improve availability and reliability of towed arrays in use on submarines in both shallow and deep water environments, and represents a critical submarine capability enhancement. The proposed project will extend and transition the telemetry, packaging and iPEN technologies developed und ...
SBIR Phase II 2014 Department of DefenseNavy -
Developing Novel Antibiotics Against Yersinia pestis
SBC: NOVOBIOTIC PHARMACEUTICALS, LLC Topic: N/ADESCRIPTION (provided by applicant): The overall goal of this project is to develop broad-spectrum antibiotics against Yersinia pestis and other important human pathogens. The potential use of engineered, multi-drug-resistant strains as agents of bioterrorism necessitates the development of new anti-Y. pestis therapies. This is a challenging goal, since the last novel class of broad-spectrum antib ...
SBIR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health